These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 23222783)
1. Setting the stage for biosimilar monoclonal antibodies. Schneider CK; Vleminckx C; Gravanis I; Ehmann F; Trouvin JH; Weise M; Thirstrup S Nat Biotechnol; 2012 Dec; 30(12):1179-85. PubMed ID: 23222783 [No Abstract] [Full Text] [Related]
2. Japanese regulation of biosimilar products: past experience and current challenges. Arato T Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746 [TBL] [Abstract][Full Text] [Related]
5. Biosimilar regulation in the EU. Kurki P; Ekman N Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076 [TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody: the corner stone of modern biotherapeutics. Xia ZN; Cai XT; Cao P Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138 [TBL] [Abstract][Full Text] [Related]
7. [Biosimilars: regulatory status for approval]. Herrero Ambrosio A Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853 [TBL] [Abstract][Full Text] [Related]
13. Biosimilar infliximab: an expert view. Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260 [TBL] [Abstract][Full Text] [Related]
14. Global regulatory standards for the approval of biosimilars. Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248 [TBL] [Abstract][Full Text] [Related]
15. Biosimilars: The US Regulatory Framework. Christl LA; Woodcock J; Kozlowski S Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877 [TBL] [Abstract][Full Text] [Related]
17. Current Japanese Regulatory Systems for Generics and Biosimilars. Kuribayashi R; Sawanobori K J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922 [TBL] [Abstract][Full Text] [Related]
18. FDA approves biosimilar version of infliximab. Traynor K Am J Health Syst Pharm; 2016 May; 73(10):604-6. PubMed ID: 27147206 [No Abstract] [Full Text] [Related]
19. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases. Braun J; Kudrin A Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985 [TBL] [Abstract][Full Text] [Related]
20. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied. Mellstedt H Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]